Paris-based biotech ABIVAX launches pivotal clinical study on hep B candidate in Asia

 

Published February 27th, 2015

 

SINGAPORE--Paris-based clinical biotech ABIVAX said it has recruited its first patient for an Asia Pacific-based pivotal Phase IIb-III clinical trial of a potential vaccine therapy of chronic hepatitis B via a controlling viral load for a much longer period of time when compared to current options.

 

To view article, click here

Press contacts

Caroline Carmagnol 

abivax@alizerp.com

+ 33 6 64 18 99 59 or
+ 33 1 44 54 36 65

 Standard: +33 1 53 83 08 41

More articles in French

Click here